Sanofi upbeat on GLP-1 diabetes drug data; Emergent wins $186M contract; Novartis smoker's cough therapy beats GSK's;

@FierceBiotech: Crucell eagerly accepts $2.3B buyout offer from J&J. Article | Follow @FierceBiotech

 @JohnCFierce: Transition's Tony Cruz gambles and fails on diabetes program, collaborating with Lilly. TT-223 bites the dust. Article | Follow @JohnCFierce

> Sanofi-Aventis says that its GLP-1 Type 2 diabetes drug, lixisenatide, significantly improved glycemic control in a late-stage trial. Sanofi has ambitious plans to expand its presence in the fast-growing diabetes drug market. Story

> Emergent BioSolutions inked a $186.6 million contract with the Department of Health and Human Services to develop a new anthrax vaccine. The five-year contract starts with a $51 million base in the first two years. News

> Novartis reports that its smoker's cough therapy, Onbrez Breezhaler, which is up for U.S. approval, proved more effective than one of GSK's treatments in a late-stage study. Report

> Eddingpharm, a specialty pharmaceutical marketing company focused on the China market, closed on a $24 million Series B financing co-led by OrbiMed Advisors Caduceus Asia Partners Fund and Domain Associates. Eddingpharm release

> Chronix Biomedical, a biomarkers company, today announced that it has completed a Series E financing that raised $1.8 million from existing and new investors. Chronix release

And Finally... Scientists say they found the ‘Homer Simpson' gene. Release

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.